SWEDISH ORPHAN/S (OTCMKTS:SWTUY) – Research analysts at Jefferies Financial Group issued their Q1 2019 EPS estimates for SWEDISH ORPHAN/S in a research note issued to investors on Wednesday, October 31st. Jefferies Financial Group analyst E. Yang anticipates that the company will post earnings of $0.27 per share for the quarter. Jefferies Financial Group also issued estimates for SWEDISH ORPHAN/S’s Q2 2019 earnings at $0.28 EPS, Q3 2019 earnings at $0.29 EPS, Q4 2019 earnings at $0.32 EPS, FY2020 earnings at $1.47 EPS, FY2021 earnings at $1.65 EPS and FY2022 earnings at $1.81 EPS.
Several other research firms have also issued reports on SWTUY. Zacks Investment Research lowered SWEDISH ORPHAN/S from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 19th. ValuEngine raised SWEDISH ORPHAN/S from a “hold” rating to a “buy” rating in a report on Thursday, July 19th.
SWTUY stock opened at $20.95 on Friday. The company has a market capitalization of $6.22 billion, a PE ratio of 41.90, a price-to-earnings-growth ratio of 2.85 and a beta of 2.12. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.00 and a quick ratio of 1.57. SWEDISH ORPHAN/S has a 12-month low of $12.55 and a 12-month high of $31.96.
About SWEDISH ORPHAN/S
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetic and lysosomal diseases. The company offers Elocta to treat haemophilia A; and Alprolix to treat haemophilia B.
Recommended Story: What is the Dividend Aristocrat Index?
Receive News & Ratings for SWEDISH ORPHAN/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SWEDISH ORPHAN/S and related companies with MarketBeat.com's FREE daily email newsletter.